AU604734B2 - Use of 2-aminoalkyl-5-pyridinols as nootropic agents and anti-depressants - Google Patents

Use of 2-aminoalkyl-5-pyridinols as nootropic agents and anti-depressants Download PDF

Info

Publication number
AU604734B2
AU604734B2 AU76279/87A AU7627987A AU604734B2 AU 604734 B2 AU604734 B2 AU 604734B2 AU 76279/87 A AU76279/87 A AU 76279/87A AU 7627987 A AU7627987 A AU 7627987A AU 604734 B2 AU604734 B2 AU 604734B2
Authority
AU
Australia
Prior art keywords
mammal
nootropically
addition salt
acid
acid addition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76279/87A
Other languages
English (en)
Other versions
AU7627987A (en
Inventor
Cesare Mondadori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of AU7627987A publication Critical patent/AU7627987A/en
Application granted granted Critical
Publication of AU604734B2 publication Critical patent/AU604734B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU76279/87A 1986-04-11 1987-07-30 Use of 2-aminoalkyl-5-pyridinols as nootropic agents and anti-depressants Ceased AU604734B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH143286 1986-04-11

Publications (2)

Publication Number Publication Date
AU7627987A AU7627987A (en) 1989-02-02
AU604734B2 true AU604734B2 (en) 1991-01-03

Family

ID=4210322

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76279/87A Ceased AU604734B2 (en) 1986-04-11 1987-07-30 Use of 2-aminoalkyl-5-pyridinols as nootropic agents and anti-depressants

Country Status (5)

Country Link
US (1) US4746670A (enExample)
EP (1) EP0241428B1 (enExample)
JP (1) JPS62242620A (enExample)
AU (1) AU604734B2 (enExample)
DE (1) DE3777432D1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK730588A (da) * 1988-02-03 1989-08-04 Asta Pharma Ag Anvendelse af pyridin-2-ethere eller pyridin-2-thioethere med en nitrogenholdig cycloalifatisk ring som antidepressivt laegemiddel
RU2145855C1 (ru) * 1999-05-26 2000-02-27 Смирнов Леонид Дмитриевич Анксиолитическое, противоалкогольное, церебропротекторное лекарственное средство

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260619A (en) * 1980-02-19 1981-04-07 Ciba-Geigy Corporation 2-Aminoalkyl-5-pyridinols

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0019739B1 (de) * 1979-05-03 1984-07-18 Ciba-Geigy Ag 2-Aminoalkyl-5-pyridinole, Verfahren zu ihrer Herstellung und pharmazeutische Präparate die diese Verbindungen enthalten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4260619A (en) * 1980-02-19 1981-04-07 Ciba-Geigy Corporation 2-Aminoalkyl-5-pyridinols

Also Published As

Publication number Publication date
DE3777432D1 (de) 1992-04-23
EP0241428A3 (en) 1990-07-04
JPS62242620A (ja) 1987-10-23
JPH0580450B2 (enExample) 1993-11-09
US4746670A (en) 1988-05-24
EP0241428B1 (de) 1992-03-18
EP0241428A2 (de) 1987-10-14
AU7627987A (en) 1989-02-02

Similar Documents

Publication Publication Date Title
Martin et al. 5-HT3 receptor antagonists reverse helpless behaviour in rats
EP0230370B1 (en) Use of specific n-methyl-d-aspartate receptor antagonists in the prevention and treatment of neurodegeneration
PT93424B (pt) Processo para a preparacao de uma composicao contendo d-cicloserina e d- -alanina para melhoria de memoria e de aprendizagem ou para tratamento de doencas psicoticas ou cognitivas
WO2008040481A1 (de) GEMISCHTE ORL1/μ-AGONISTEN ZUR BEHANDLUNG VON SCHMERZ
CZ297570B6 (cs) Farmaceutický prípravek obsahující 2-acetoxypyridinový derivát a aspirin, které spolu pusobí v synergickém úcinku, kit jej obsahující a pouzití
AU579028B2 (en) Anticonvulsant compositions and method
KR910019618A (ko) 발기부전증 치료용 제약 조성물
JP2625457B2 (ja) 吐気又は嘔吐を防止又は軽減するための薬剤
NZ237422A (en) Use of spiperone (derivatives) to suppress the immune response in mammals
EP1014974A1 (en) Treatment of schizophrenia and psychosis
US5180729A (en) Use of sigma receptor antagonists for treatment of cocaine abuse
AU604734B2 (en) Use of 2-aminoalkyl-5-pyridinols as nootropic agents and anti-depressants
JP2575569B2 (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
Wang et al. Alkaloids of Chinese aconitum plants
RU2706001C2 (ru) Способ для лечения болезней мотонейронов
JPH0358328B2 (enExample)
US4533551A (en) Method of treating arthritis with etodolac
KR19990067353A (ko) 외상으로 인한 뇌 손상 치룡용 의약제제
Makovec et al. Antispasdomic activity on the gallbladder of the mouse of CR 1409 (Lorglumide) a potent antagonist of peripheral CCK
RS4904A (sr) Farmaceutski preparati za tretman smanjenih ili oštećenih spoznajnih funkcija
Matsui et al. Ataxia-ameliorating effects of YM-14673, a potent analog of thyrotropin releasing hormone, in ataxic mutant mice
IE903945A1 (en) Therapeutic agents
WO2002011766A3 (en) Use of 5ht4 receptor antagonists in the manufacture of a medicament for the prophylaxis or treatment of atrial fibrillation
JP2004500333A (ja) 胃腸管障害の治療における、２−アミノ−４−（４−フルオロナフタ−１−イル）−６−イソプロピルピリミジンの使用
Rotrosen et al. Experimental dystonia induced by quaternary‐chlorpromazine